한글목차

세계 그레이브스병 시장은 2024년 4억 1,010만 달러로 추정되며, 2024-2031년 연평균 4.8% 성장하여 2031년에는 5억 7,020만 달러에 달할 것으로 예상됩니다.

그림 1. 그레이브스병 시장 점유율(%), 지역별, 2024년

독성 미만성 갑상선종으로도 알려진 그레이브스병은 갑상선 호르몬이 과다 분비되는 자가면역질환입니다. 갑상선 기능 항진증의 가장 흔한 원인입니다. 그레이브스병은 면역체계가 항체를 만들어 갑상선을 자극하여 갑상선 호르몬을 과도하게 분비하게 만들어 발병합니다. 과도한 갑상선 호르몬은 신체의 많은 기능을 가속화합니다. 그레이브스병의 흔한 증상으로는 떨림, 불안, 체중 감소, 심계항진, 더위에 대한 민감성 등이 있습니다. 그레이브스병은 전체 인구의 약 0.5%가 앓고 있으며, 여성에게 더 많이 발생합니다. 이 질환은 유전적 요인이 있는 것으로 여겨지며, 가족 내에서 발병하는 경우가 많습니다. 그레이브스병은 완치되는 질환은 아니지만 항갑상선제, 방사성 요오드 치료, 갑상선의 일부 또는 전부를 제거하는 수술로 효과적으로 치료할 수 있습니다.

시장 역학:

세계 그레이브스병 시장의 성장은 고령화 인구의 증가와 갑상선 질환의 유병률 증가 등의 요인에 의해 주도되고 있습니다. 미국 갑상선협회에 따르면, 매년 미국 인구의 약 0.5%가 갑상선 질환을 앓고 있습니다. 의료비 지출 증가, 새로운 치료 옵션의 가용성, 질병 진단 및 관리에 대한 인식 증가도 시장 성장의 원동력이 될 수 있습니다. 그러나 체중 증가, 탈모, 간 손상 등 항갑상선 약물의 부작용이 시장 성장에 걸림돌이 될 수 있습니다. 또한, 수술 및 방사성 요오드 요법에 따른 높은 비용도 시장 성장을 저해하는 요인으로 작용할 수 있습니다. 새로운 약물 분자 및 병용 요법에 대한 지속적인 약물 혁신과 임상시험은 예측 기간 동안 시장 성장에 유리한 기회를 제공할 수 있습니다.

본 조사의 주요 특징

• 이 보고서는 2023년을 기준 연도로 하여 예측 기간(2024-2031년)의 시장 규모와 연평균 성장률(CAGR)을 통해 전 세계 그레이브스병 시장을 상세히 분석합니다.
• 다양한 부문에 걸친 잠재적 수익 기회를 파악하고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 그레이브스병 시장의 주요 기업 개요을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 그레이브스병 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 그레이브스병 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 규제 시나리오
• 인수와 제휴 시나리오
• 자금 조달과 투자
• PEST 분석
• Porters 분석

제4장 세계의 그레이브스병 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 이니셔티브
• COVID-19의 시장에 대한 영향

제5장 세계의 그레이브스병 시장, 치료법별, 2019-2031년(100만 달러)

• 소개
• 항갑상선제
• 베타 차단제
• 요오드 요법
• 방사성 요오드 요법
• 기타

제6장 세계의 그레이브스병 시장, 투여 경로별, 2019-2031년(100만 달러)

• 소개
• 경구
• 비경구
• 기타

제7장 세계의 그레이브스병 시장, 유통 채널별, 2019-2031년(100만 달러)

• 소개
• 병원 약국
• 소매 약국
• 온라인 약국

제8장 세계의 그레이브스병 시장, 지역별, 2019-2031년(100만 달러)

• 소개
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동

제9장 경쟁 상황

• 기업 개요
  • AbbVie Inc.
  • Pfizer Inc.
  • RLC LABS, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Mylan NV
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology(Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

제10장 애널리스트의 추천사항

• Wheel of Fortune
• Coherent Opportunity Map

제11장 참고문헌과 조사 방법

• 참고문헌
• 조사 방법

영문목차

Global graves' disease (overactive thyroid) market is estimated to be valued at USD 410.1 Mn in 2024 and is expected to reach USD 570.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

Figure 1. Graves' Disease (Overactive Thyroid) Market Share (%), By Region, 2024

Graves' disease, also known as toxic diffuse goiter, is an autoimmune disease that results in overproduction of thyroid hormones (hyperthyroidism). It is the most common cause of hyperthyroidism. Graves' disease develops when the immune system makes antibodies that stimulate the thyroid gland to grow and produce excess thyroid hormones. Excess thyroid hormones causes speeding up of many of the body's functions. Common symptoms of Graves' disease include tremors, anxiety, weight loss, heart palpitations, and heat intolerance. Graves' disease affects about 0.5% of the general population, although the disease is more common in women. The disease is believed to have a genetic component, and often runs in families. Although it is not curable, Graves' disease can be effectively treated by antithyroid medications, radioactive iodine therapy, or surgery to remove part or all of the thyroid gland.

Market Dynamics:

Global graves' disease (overactive thyroid) market growth is driven by factors like growing aging population and increasing prevalence of thyroid disorders. According to American Thyroid Association, Graves' disease affects about 0.5% of the population in the U.S. every year. Increasing healthcare expenditure, availability of newer treatment options, and rising awareness about disease diagnosis and management can also drive the market growth. However, side effects associated with antithyroid medications such as weight gain, hair loss and liver damage can hinder the market growth. High costs involved in surgeries and radioactive iodine therapy can also hamper the market growth. Ongoing drug innovations and clinical trials on newer drug molecules and combination therapies can offer lucrative opportunities for market growth over the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global graves' disease (overactive thyroid) market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global graves' disease (overactive thyroid) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Pfizer Inc., RLC LABS, Inc., Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings Limited, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol) Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co., Ltd., Cara Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global graves' disease (overactive thyroid) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global graves' disease (overactive thyroid) market

Detailed Segmentation-

• By Treatment
  • Anti-thyroid Drugs
  • Beta Blockers
  • Iodine Therapy
  • Radioactive Iodine Therapy
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Pfizer Inc.
  • RLC LABS, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Mylan N.V.
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology (Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Graves' Disease (Overactive Thyroid) Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Graves' Disease (Overactive Thyroid) Market, By Treatment, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Anti-thyroid Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Beta Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Iodine Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Radioactive Iodine Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Graves' Disease (Overactive Thyroid) Market, By Route of Administration, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Graves' Disease (Overactive Thyroid) Market, By Distribution Channel, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Graves' Disease (Overactive Thyroid) Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • RLC LABS, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aspen Pharmacare Holdings Limited
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Horizon Therapeutics plc
  • Alara Pharmaceutical Corporation
  • Antares Pharma, Inc.
  • Apitope Technology (Bristol) Ltd.
  • IONIS Pharmaceuticals, Inc.
  • Immunovant, Inc.
  • HanAll Biopharma Co., Ltd.
  • Cara Therapeutics

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact